| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Research and development | 100,057 | 66,507 | -27,981* | 58,989 |
| General and administrative | 18,573 | 22,872 | 15,746* | 14,798 |
| Other license income | - | - | 25,000* | - |
| Gains on sale of non-financial assets | - | - | 2,562* | - |
| Total operating expenses | 118,630 | 89,379 | -39,798 | 73,787 |
| Gain from operations | -118,630 | -89,379 | 39,798* | -73,787 |
| Interest and other income, net | 12,705 | 13,601 | 10,205* | 8,183 |
| Gain before provision for income taxes | -105,925 | -75,778 | 50,003* | -65,604 |
| Provision for income taxes | 234 | 190 | 145* | 108 |
| Net gain attributable to ordinary shareholders | -106,159 | -75,968 | 49,858* | -65,712 |
| Unrealized loss on investments, net | -1,250 | -3,249 | 125 | 463 |
| Total other comprehensive loss | -1,250 | -3,249 | 125* | 463 |
| Comprehensive gain | -107,409 | -79,217 | 49,983 | -65,249 |
| Basic EPS | -0.49 | -0.35 | 0.271 | -0.37 |
| Diluted EPS | -0.49 | -0.35 | 0.278 | -0.37 |
| Basic Average Shares | 217,957,000 | 217,326,000 | 184,672,000 | 175,469,000 |
| Diluted Average Shares | 217,957,000 | 217,326,000 | 179,723,000 | 175,469,000 |
Structure Therapeutics Inc. (GPCR)
Structure Therapeutics Inc. (GPCR)